Not applicableStudy completedNCT04920747
What this trial is testing
Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
Who this might be right for
HER2-positive Gastric CancerMetastatic CancerDocetaxel+1 more
Centre Hospitalier Universitaire de Besancon 65